Kamada Announces $11.4M Agreement To Supply VARIZIG To An Undisclosed International Organization

Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America   Product Supply Expected During
  • Procurement Agreement Following New Tender Won from an International Organization Operating Principally in Latin America
  • Product Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023

REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization, operating principally in Latin America. The supply of the product is expected to occur from the fourth quarter of 2022 through the first half of 2023.

“We are extremely pleased with this significant supply agreement, which strongly validates our ability to grow the sales of our newly acquired portfolio of four FDA-approved plasma-derived specialty IgGs in the international markets,” said Amir London, Kamada’s Chief Executive Officer. “This order, which is based on winning a new tender, is indicative of the significant commercial potential for these products in the international markets, beyond the U.S. and Canada, and we intend to continue pursuing additional commercial contracts in key strategic territories.”

VARIZIG [Varicella Zoster Immune Globulin (Human)], one of four recently acquired FDA-approved commercial products by Kamada, contains antibodies specific for the Varicella zoster virus, and is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups, including immunocompromised children, newborns, and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients. The U.S. Centers for Disease Control (CDC) recommends VARIZIG for postexposure prophylaxis of varicella for persons at high-risk for severe disease who lack evidence of immunity to varicella. The product is the sole FDA-approved IgG product for this indication.

VARIZIG is manufactured by Emergent BioSolutions (NYSE:EBS) at their facility in Winnipeg, MB, Canada, under a contract development and manufacturing (CDMO) service agreement.

Related Posts
Read More

Synchronoss Technologies

Synchronoss Technologies, Inc. ("Synchronoss" or the "Company") (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced strong growth in Asia Pacific, primarily fueled by growth in its Advanced Messaging business


Read More

A Guide To Evaluating Cannabis Stocks: Financial Metrics, Leverage, Governance, Dilution And More

Zuanic & Associates (Z&A), has launched its research service with thematic and macro reports, followed by selective equity stock coverage. Its expert evaluation framework guides you in making informed choices for cannabis stock investments.